Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 945

1.

Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease.

Cazzola M, Page C, Calzetta L, Matera MG.

Pharm Pat Anal. 2019 Jan 18. doi: 10.4155/ppa-2018-0030. [Epub ahead of print]

PMID:
30657422
2.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jan 11. doi: 10.1038/s41375-018-0351-2. [Epub ahead of print]

PMID:
30635634
3.

Introduction to a review series on iron metabolism and its disorders.

Coates TD, Cazzola M.

Blood. 2019 Jan 3;133(1):1-2. doi: 10.1182/blood-2018-10-876466. Epub 2018 Nov 14. No abstract available.

PMID:
30429162
4.

Varenicline for long term smoking cessation in patients with COPD.

Hernández Zenteno RJ, Lara DF, Venegas AR, Sansores RH, Pineda JR, Trujillo FF, Pérez Padilla JR, Matera MG, Cazzola M.

Pulm Pharmacol Ther. 2018 Dec;53:116-120. doi: 10.1016/j.pupt.2018.11.001. Epub 2018 Nov 3.

PMID:
30399395
5.

An inhaled "bifunctional" dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD.

Cazzola M, Page C.

Eur Respir J. 2018 Nov 1;52(5). pii: 1801675. doi: 10.1183/13993003.01675-2018. Print 2018 Nov. No abstract available.

PMID:
30385603
6.

Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents.

Matera MG, Rogliani P, Ora J, Cazzola M.

Expert Opin Pharmacother. 2018 Oct 25:1-11. doi: 10.1080/14656566.2018.1534957. [Epub ahead of print]

PMID:
30359143
7.

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review.

Rogliani P, Calzetta L, Braido F, Cazzola M, Clini E, Pelaia G, Rossi A, Scichilone N, Di Marco F.

Int J Chron Obstruct Pulmon Dis. 2018 Oct 4;13:3115-3130. doi: 10.2147/COPD.S170606. eCollection 2018. Review.

8.

Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis.

Cazzola M, Rogliani P, Calzetta L, Matera MG.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801586. doi: 10.1183/13993003.01586-2018. Print 2018 Dec. Review.

PMID:
30309975
9.

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.

Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Merli M, Pietra D, Barbui T, Rotunno G, Cazzola M, Giorgino T, Vannucchi AM, Passamonti F.

Blood Cancer J. 2018 Sep 21;8(10):89. doi: 10.1038/s41408-018-0128-x. No abstract available.

10.

Rebuttal From Drs Cazzola and Matera.

Cazzola M, Matera MG.

Chest. 2018 Oct;154(4):751-752. doi: 10.1016/j.chest.2018.06.023. No abstract available.

PMID:
30290927
11.

POINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? Yes.

Cazzola M, Matera MG.

Chest. 2018 Oct;154(4):746-748. doi: 10.1016/j.chest.2018.06.022. No abstract available.

PMID:
30290925
12.

Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease.

Matera MG, Rinaldi B, Page C, Rogliani P, Cazzola M.

Expert Opin Drug Metab Toxicol. 2018 Oct;14(10):1101-1111. doi: 10.1080/17425255.2018.1530215. Epub 2018 Oct 9. Review.

PMID:
30261755
13.

Infection perturbs Bach2- and Bach1-dependent erythroid lineage 'choice' to cause anemia.

Kato H, Itoh-Nakadai A, Matsumoto M, Ishii Y, Watanabe-Matsui M, Ikeda M, Ebina-Shibuya R, Sato Y, Kobayashi M, Nishizawa H, Suzuki K, Muto A, Fujiwara T, Nannya Y, Malcovati L, Cazzola M, Ogawa S, Harigae H, Igarashi K.

Nat Immunol. 2018 Oct;19(10):1059-1070. doi: 10.1038/s41590-018-0202-3. Epub 2018 Sep 24.

PMID:
30250186
14.

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology.

D'Urzo AD, Cazzola M, Hanania NA, Buhl R, Maleki-Yazdi MR.

Int J Chron Obstruct Pulmon Dis. 2018 Sep 7;13:2805-2819. doi: 10.2147/COPD.S113306. eCollection 2018. Review.

15.

Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2).

Calzetta L, Hanania NA, Dini FL, Goldstein MF, Fairweather WR, Howard WW, Cazzola M.

Pulm Pharmacol Ther. 2018 Dec;53:20-26. doi: 10.1016/j.pupt.2018.09.007. Epub 2018 Sep 13.

16.

Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS.

Miyazaki Y, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Santini V, Lübbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SMM, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL.

Leuk Res. 2018 Oct;73:51-57. doi: 10.1016/j.leukres.2018.08.022. Epub 2018 Sep 6.

17.

Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia.

Shiozawa Y, Malcovati L, Gallì A, Sato-Otsubo A, Kataoka K, Sato Y, Watatani Y, Suzuki H, Yoshizato T, Yoshida K, Sanada M, Makishima H, Shiraishi Y, Chiba K, Hellström-Lindberg E, Miyano S, Ogawa S, Cazzola M.

Nat Commun. 2018 Sep 7;9(1):3649. doi: 10.1038/s41467-018-06063-x.

18.

Benefits and risks of JAK inhibition.

Arcaini L, Cazzola M.

Blood. 2018 Aug 16;132(7):675-676. doi: 10.1182/blood-2018-07-858720. No abstract available.

PMID:
30115632
19.

Green Tea Polyphenols Coupled with a Bioactive Titanium Alloy Surface: In Vitro Characterization of Osteoinductive Behavior through a KUSA A1 Cell Study.

Cazzola M, Ferraris S, Boschetto F, Rondinella A, Marin E, Zhu W, Pezzotti G, Vernè E, Spriano S.

Int J Mol Sci. 2018 Aug 1;19(8). pii: E2255. doi: 10.3390/ijms19082255.

20.

Emerging antibacterial and antiviral drugs for treating respiratory tract infections.

Mantero M, Rogliani P, Cazzola M, Blasi F, Di Pasquale M.

Expert Opin Emerg Drugs. 2018 Sep;23(3):185-199. doi: 10.1080/14728214.2018.1504020. Epub 2018 Jul 30. Review.

PMID:
30032674
21.

Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network.

Zappasodi P, Marbello L, Borlenghi E, Fumagalli M, Bernardi M, Fracchiolla N, Mancini V, Da Vià M, Ravano E, Cerqui E, Ferretti VV, Rocca B, Calvello C, Cazzola M, Castagnola C, Rossi G.

Ann Hematol. 2018 Jul 15. doi: 10.1007/s00277-018-3424-4. [Epub ahead of print]

PMID:
30009341
22.

Pregnancy outcome and management of 25 pregnancies in women with polycythemia vera.

Bertozzi I, Rumi E, Cavalloni C, Cazzola M, Fabris F, Randi ML.

Am J Hematol. 2018 Sep;93(9):E234-E235. doi: 10.1002/ajh.25210. Epub 2018 Aug 31. No abstract available.

PMID:
29989197
23.

Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease.

Calzetta L, Matera MG, Rogliani P, Cazzola M.

Expert Rev Respir Med. 2018 Aug;12(8):693-708. doi: 10.1080/17476348.2018.1495562. Epub 2018 Jul 17.

PMID:
29972340
24.

Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach?

Cazzola M, Matera MG, Rogliani P, Calzetta L.

Expert Opin Investig Drugs. 2018 Jul;27(7):573-581. doi: 10.1080/13543784.2018.1492548. Epub 2018 Jul 4. Review.

PMID:
29972333
25.

Tiotropium could provide benefits in the early stage of COPD, but further studies are needed.

Cazzola M, Rogliani P.

BMJ Evid Based Med. 2018 Oct;23(5):183-184. doi: 10.1136/bmjebm-2018-110940. Epub 2018 Jun 27. Review. No abstract available.

PMID:
29950311
26.

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.

Pellagatti A, Armstrong RN, Steeples V, Sharma E, Repapi E, Singh S, Sanchi A, Radujkovic A, Horn P, Dolatshad H, Roy S, Broxholme J, Lockstone H, Taylor S, Giagounidis A, Vyas P, Schuh A, Hamblin A, Papaemmanuil E, Killick S, Malcovati L, Hennrich ML, Gavin AC, Ho AD, Luft T, Hellström-Lindberg E, Cazzola M, Smith CWJ, Smith S, Boultwood J.

Blood. 2018 Sep 20;132(12):1225-1240. doi: 10.1182/blood-2018-04-843771. Epub 2018 Jun 21.

PMID:
29930011
27.

Combining Dual Bronchodilation and β-Blockade in Patients With an Overlap Between COPD and Cardiovascular Diseases.

Cazzola M, Matera MG.

Chest. 2018 Jun;153(6):1289-1291. doi: 10.1016/j.chest.2018.01.032. No abstract available.

PMID:
29884246
28.

Zeta Potential Measurements on Solid Surfaces for in Vitro Biomaterials Testing: Surface Charge, Reactivity Upon Contact With Fluids and Protein Absorption.

Ferraris S, Cazzola M, Peretti V, Stella B, Spriano S.

Front Bioeng Biotechnol. 2018 May 9;6:60. doi: 10.3389/fbioe.2018.00060. eCollection 2018.

29.

Editorial overview: Respiratory: Pulmonary pharmacology - It is time for a breath of fresh air.

Cazzola M, Matera MG.

Curr Opin Pharmacol. 2018 Jun;40:iv-viii. doi: 10.1016/j.coph.2018.05.011. Epub 2018 May 30. No abstract available.

PMID:
29859765
30.

Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells.

Matera MG, Calzetta L, Gritti G, Gallo L, Perfetto B, Donnarumma G, Cazzola M, Rogliani P, Donniacuo M, Rinaldi B.

Eur J Pharmacol. 2018 Aug 5;832:114-119. doi: 10.1016/j.ejphar.2018.05.023. Epub 2018 May 18.

PMID:
29782855
31.

Chronic Obstructive Pulmonary Disease and Stroke.

Corlateanu A, Covantev S, Mathioudakis AG, Botnaru V, Cazzola M, Siafakas N.

COPD. 2018 Jun-Aug;15(4):405-413. doi: 10.1080/15412555.2018.1464551. Epub 2018 May 10.

PMID:
29746193
32.

Efficacy and safety profile of xanthines in COPD: a network meta-analysis.

Cazzola M, Calzetta L, Barnes PJ, Criner GJ, Martinez FJ, Papi A, Gabriella Matera M.

Eur Respir Rev. 2018 May 2;27(148). pii: 180010. doi: 10.1183/16000617.0010-2018. Print 2018 Jun 30. Review.

33.

The safety of dual bronchodilation on cardiovascular serious adverse events in COPD.

Rogliani P, Ora J, Matera MG, Cazzola M, Calzetta L.

Expert Opin Drug Saf. 2018 Jun;17(6):589-596. doi: 10.1080/14740338.2018.1472232. Epub 2018 May 14. Review.

PMID:
29716427
34.

Indacaterol/Glycopyrronium in Clinical Practice: The Italian Experience.

Cazzola M.

Respiration. 2018;95 Suppl 1:1-2. doi: 10.1159/000486881. Epub 2018 Apr 27. No abstract available.

35.

Impact of doxofylline in COPD: A pairwise meta-analysis.

Cazzola M, Calzetta L, Rogliani P, Page C, Matera MG.

Pulm Pharmacol Ther. 2018 Aug;51:1-9. doi: 10.1016/j.pupt.2018.04.010. Epub 2018 Apr 26.

36.

Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways.

Calzetta L, Matera MG, Facciolo F, Cazzola M, Rogliani P.

Respir Res. 2018 Apr 12;19(1):65. doi: 10.1186/s12931-018-0770-7.

37.

N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation.

Calzetta L, Rogliani P, Facciolo F, Rinaldi B, Cazzola M, Matera MG.

Biomed Pharmacother. 2018 Jul;103:1-8. doi: 10.1016/j.biopha.2018.04.011. Epub 2018 Apr 24.

38.

Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy.

Calzetta L, Matera MG, Cazzola M.

Curr Opin Pharmacol. 2018 Jun;40:95-103. doi: 10.1016/j.coph.2018.03.011. Epub 2018 Apr 4. Review.

PMID:
29626716
39.

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Merli M, Pietra D, Casalone R, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Passamonti F.

Haematologica. 2018 Sep;103(9):e392-e394. doi: 10.3324/haematol.2017.185751. Epub 2018 Apr 5. No abstract available.

40.

Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis.

Rogliani P, Matera MG, Puxeddu E, Mantero M, Blasi F, Cazzola M, Calzetta L.

Pulm Pharmacol Ther. 2018 Jun;50:28-37. doi: 10.1016/j.pupt.2018.03.004. Epub 2018 Mar 30.

PMID:
29609004
41.

Is ICS-LAMA an alternative option to treat patients with COPD?

Rogliani P, Calzetta L, Cazzola M.

Lancet Respir Med. 2018 May;6(5):316-317. doi: 10.1016/S2213-2600(18)30139-5. Epub 2018 Apr 5. No abstract available.

PMID:
29605621
42.

MYD88 mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4.

Guerrera ML, Tsakmaklis N, Xu L, Yang G, Demos M, Kofides A, Chan GG, Manning RJ, Liu X, Chen JG, Munshi M, Patterson CJ, Castillo JJ, Dubeau T, Gustine J, Carrasco RD, Arcaini L, Varettoni M, Cazzola M, Treon SP, Hunter ZR.

Haematologica. 2018 Sep;103(9):e408-e411. doi: 10.3324/haematol.2018.190181. Epub 2018 Mar 29. No abstract available.

43.

Improvement in the management of chronic obstructive pulmonary disease following a clinical educational program: results from a prospective cohort study in the Sicilian general practice setting.

Ferrara R, Ientile V, Piccinni C, Pasqua A, Pecchioli S, Fontana A, Alecci U, Scoglio R, Magliozzo F, Torrisi SE, Vancheri C, Vitulo P, Fantaci G, Ferrajolo C, Cazzola M, Cricelli C, Caputi AP, Trifirò G.

NPJ Prim Care Respir Med. 2018 Mar 23;28(1):10. doi: 10.1038/s41533-018-0077-7.

44.

Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPD.

Donner CF, Amaducci S, Bacci E, Baldacci S, Bartoli ML, Beghi GM, Benfante A, Brighindi S, Casali L, Castiglia D, Cazzola M, Celi A, Cianchetti S, Colombo G, Crimi C, Dente FL, Di Maria G, Di Maria A, Latorre M, Lavorini F, Maio S, Mannini C, Messina R, Paggiaro PL, Pignatti P, Price D, Scichilone N, Simoni M, Spanevello A, Stagno d'Alcontres M, Tan S, Torchio R, Viegi G, Visca D, Wouters EFM, Yu Hui Xin S.

Monaldi Arch Chest Dis. 2018 Feb 2;88(1):886. doi: 10.4081/monaldi.2018.886.

45.

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.

De Stefano V, Carobbio A, Di Lazzaro V, Guglielmelli P, Iurlo A, Finazzi MC, Rumi E, Cervantes F, Elli EM, Randi ML, Griesshammer M, Palandri F, Bonifacio M, Hernandez-Boluda JC, Cacciola R, Miroslava P, Carli G, Beggiato E, Ellis MH, Musolino C, Gaidano G, Rapezzi D, Tieghi A, Lunghi F, Loscocco GG, Cattaneo D, Cortelezzi A, Betti S, Rossi E, Finazzi G, Censori B, Cazzola M, Bellini M, Arellano-Rodrigo E, Bertozzi I, Sadjadian P, Vianelli N, Scaffidi L, Gomez M, Cacciola E, Vannucchi AM, Barbui T.

Blood Cancer J. 2018 Feb 28;8(3):25. doi: 10.1038/s41408-018-0048-9.

46.

How does race/ethnicity influence pharmacological response to asthma therapies?

Cazzola M, Calzetta L, Matera MG, Hanania NA, Rogliani P.

Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):435-446. doi: 10.1080/17425255.2018.1449833. Epub 2018 Mar 12. Review.

PMID:
29528249
47.

Benralizumab for the treatment of asthma.

Matera MG, Rogliani P, Calzetta L, Canonica GW, Cazzola M.

Drugs Today (Barc). 2017 Dec;53(12):633-645. doi: 10.1358/dot.2017.53.12.2736670. Review.

PMID:
29517082
48.

A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD.

Matera MG, Calzetta L, Puxeddu E, Rogliani P, Cazzola M.

Expert Opin Drug Saf. 2018 May;17(5):509-517. doi: 10.1080/14740338.2018.1448786. Epub 2018 Mar 8.

PMID:
29505318
49.

Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.

Cazzola M, Matera MG, Levi-Schaffer F, Rogliani P.

Expert Opin Drug Saf. 2018 Apr;17(4):429-435. doi: 10.1080/14740338.2018.1446940. Epub 2018 Mar 8. Review.

PMID:
29486600
50.

Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how.

Calzetta L, Matera MG, Rogliani P, Cazzola M.

Expert Rev Respir Med. 2018 Apr;12(4):261-264. doi: 10.1080/17476348.2018.1442216. Epub 2018 Feb 19. No abstract available.

PMID:
29451042

Supplemental Content

Loading ...
Support Center